Vertex Pharmaceuticals Incorporated (VRTX)
VRTX's Q2 Earnings Lag Estimates, Revenues Top, 2026 Sales View Raised
Vertex's Q2 earnings miss estimates, but revenues beat. It lifts its 2026 sales outlook, and sees growing contributions from newer products.
VRTX Q2 Earnings Call Highlights Launch Momentum & Higher Outlook
Vertex raises its 2026 revenue outlook as CF growth, newer products and a near-term renal launch strengthen its diversification push.
Vertex Pharmaceuticals Incorporated (VRTX) Q2 2026 Earnings Call Transcript
Vertex Pharmaceuticals Incorporated (VRTX) Q2 2026 Earnings Call Transcript
Vertex (VRTX) Reports Q2 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Vertex (VRTX) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Vertex Pharmaceuticals (VRTX) Q2 Earnings Lag Estimates
Vertex Pharmaceuticals (VRTX) came out with quarterly earnings of $4.73 per share, missing the Zacks Consensus Estimate of $4.79 per share. This compares to earnings of $4.52 per share a year ago.
Vertex (VRTX) Q2 Earnings Preview: What You Should Know Beyond the Headline Estimates
Evaluate the expected performance of Vertex (VRTX) for the quarter ended June 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Vertex Pharmaceuticals (VRTX) Exceeds Market Returns: Some Facts to Consider
Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $490.39, moving +2.38% from the previous trading session.
Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know
Vertex (VRTX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: Should You Buy?
Vertex (VRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Vertex Pharmaceuticals (VRTX) Sees a More Significant Dip Than Broader Market: Some Facts to Know
In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $472.57, marking a -1.96% move from the previous day.
Why Vertex Pharmaceuticals (VRTX) Dipped More Than Broader Market Today
In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $480.5, denoting a -1.06% move from the preceding trading day.
Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It
Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
